295 related articles for article (PubMed ID: 23008736)
1. Immunological evaluation and comparison of different EV71 vaccine candidates.
Chou AH; Liu CC; Chang JY; Lien SP; Guo MS; Tasi HP; Hsiao KN; Liu SJ; Sia C; Wu SC; Lee MS; Hsiao CH; Wang JR; Chow YH; Chong P
Clin Dev Immunol; 2012; 2012():831282. PubMed ID: 23008736
[TBL] [Abstract][Full Text] [Related]
2. Production of EV71 vaccine candidates.
Chong P; Hsieh SY; Liu CC; Chou AH; Chang JY; Wu SC; Liu SJ; Chow YH; Su IJ; Klein M
Hum Vaccin Immunother; 2012 Dec; 8(12):1775-83. PubMed ID: 22992566
[TBL] [Abstract][Full Text] [Related]
3. Identification and characterization of a cross-neutralization epitope of Enterovirus 71.
Liu CC; Chou AH; Lien SP; Lin HY; Liu SJ; Chang JY; Guo MS; Chow YH; Yang WS; Chang KH; Sia C; Chong P
Vaccine; 2011 Jun; 29(26):4362-72. PubMed ID: 21501643
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity studies of bivalent inactivated virions of EV71/CVA16 formulated with submicron emulsion systems.
Lin CW; Liu CC; Lu TC; Liu SJ; Chow YH; Chong P; Huang MH
Biomed Res Int; 2014; 2014():670506. PubMed ID: 25006583
[TBL] [Abstract][Full Text] [Related]
5. Neutralizing antibodies induced by recombinant virus-like particles of enterovirus 71 genotype C4 inhibit infection at pre- and post-attachment steps.
Ku Z; Ye X; Huang X; Cai Y; Liu Q; Li Y; Su Z; Huang Z
PLoS One; 2013; 8(2):e57601. PubMed ID: 23451250
[TBL] [Abstract][Full Text] [Related]
6. Immunological and biochemical characterization of coxsackie virus A16 viral particles.
Chong P; Guo MS; Lin FH; Hsiao KN; Weng SY; Chou AH; Wang JR; Hsieh SY; Su IJ; Liu CC
PLoS One; 2012; 7(11):e49973. PubMed ID: 23226233
[TBL] [Abstract][Full Text] [Related]
7. Structures of Coxsackievirus A16 Capsids with Native Antigenicity: Implications for Particle Expansion, Receptor Binding, and Immunogenicity.
Ren J; Wang X; Zhu L; Hu Z; Gao Q; Yang P; Li X; Wang J; Shen X; Fry EE; Rao Z; Stuart DI
J Virol; 2015 Oct; 89(20):10500-11. PubMed ID: 26269176
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of monovalent and bivalent vaccines against lethal Enterovirus 71 and Coxsackievirus A16 infection in newborn mice.
Sun S; Jiang L; Liang Z; Mao Q; Su W; Zhang H; Li X; Jin J; Xu L; Zhao D; Fan P; An D; Yang P; Lu J; Lv X; Sun B; Xu F; Kong W; Jiang C
Hum Vaccin Immunother; 2014; 10(10):2885-95. PubMed ID: 25483672
[TBL] [Abstract][Full Text] [Related]
9. Poorly neutralizing polyclonal antibody in vitro against coxsackievirus A16 circulating strains can prevent a lethal challenge in vivo.
Yao X; Mao Q; Li Y; Hao C; Bian L; Chen P; Gao F; Wu X; Lu W; Gao Q; Li X; Liang Z
Hum Vaccin Immunother; 2018 May; 14(5):1275-1282. PubMed ID: 29337652
[TBL] [Abstract][Full Text] [Related]
10. Recombinant adeno-vaccine expressing enterovirus 71-like particles against hand, foot, and mouth disease.
Tsou YL; Lin YW; Shao HY; Yu SL; Wu SR; Lin HY; Liu CC; Huang C; Chong P; Chow YH
PLoS Negl Trop Dis; 2015 Apr; 9(4):e0003692. PubMed ID: 25855976
[TBL] [Abstract][Full Text] [Related]
11. Crystal Structures of Yeast-Produced Enterovirus 71 and Enterovirus 71/Coxsackievirus A16 Chimeric Virus-Like Particles Provide the Structural Basis for Novel Vaccine Design against Hand-Foot-and-Mouth Disease.
Lyu K; He YL; Li HY; Chen R
J Virol; 2015 Jun; 89(12):6196-208. PubMed ID: 25833050
[TBL] [Abstract][Full Text] [Related]
12. A virus-like particle-based tetravalent vaccine for hand, foot, and mouth disease elicits broad and balanced protective immunity.
Zhang W; Dai W; Zhang C; Zhou Y; Xiong P; Wang S; Ye X; Liu Q; Zhou D; Huang Z
Emerg Microbes Infect; 2018 May; 7(1):94. PubMed ID: 29777102
[TBL] [Abstract][Full Text] [Related]
13. Induction of a high-titered antibody response using HIV gag-EV71 VP1-based virus-like particles with the capacity to protect newborn mice challenged with a lethal dose of enterovirus 71.
Wang X; Dong K; Long M; Lin F; Gao Z; Wang L; Zhang Z; Chen X; Dai Y; Wang H; Zhang H
Arch Virol; 2018 Jul; 163(7):1851-1861. PubMed ID: 29582164
[TBL] [Abstract][Full Text] [Related]
14. Protection against enterovirus 71 with neutralizing epitope incorporation within adenovirus type 3 hexon.
Tian X; Su X; Li X; Li H; Li T; Zhou Z; Zhong T; Zhou R
PLoS One; 2012; 7(7):e41381. PubMed ID: 22848478
[TBL] [Abstract][Full Text] [Related]
15. A new EV71 VP3 epitope in norovirus P particle vector displays neutralizing activity and protection in vivo in mice.
Jiang L; Fan R; Sun S; Fan P; Su W; Zhou Y; Gao F; Xu F; Kong W; Jiang C
Vaccine; 2015 Nov; 33(48):6596-603. PubMed ID: 26529072
[TBL] [Abstract][Full Text] [Related]
16. Immunological and biochemical characterizations of coxsackievirus A6 and A10 viral particles.
Liu CC; Guo MS; Wu SR; Lin HY; Yang YT; Liu WC; Chow YH; Shieh DB; Wang JR; Chong P
Antiviral Res; 2016 May; 129():58-66. PubMed ID: 26899790
[TBL] [Abstract][Full Text] [Related]
17. Determinants of EV71 immunogenicity and protection against lethal challenge in a mouse model.
Chang J; Li J; Wei W; Liu X; Liu G; Yang J; Zhang W; Yu XF
Immunol Res; 2015 Jul; 62(3):306-15. PubMed ID: 26025091
[TBL] [Abstract][Full Text] [Related]
18. VP1 of Enterovirus 71 Protects Mice Against Enterovirus 71 and Coxsackievirus B3 in Lethal Challenge Experiment.
Chen FH; Liu X; Fang HL; Nan N; Li Z; Ning NZ; Luo DY; Li T; Wang H
Front Immunol; 2019; 10():2564. PubMed ID: 31787970
[TBL] [Abstract][Full Text] [Related]
19. Pilot scale production of highly efficacious and stable enterovirus 71 vaccine candidates.
Chou AH; Liu CC; Chang CP; Guo MS; Hsieh SY; Yang WH; Chao HJ; Wu CL; Huang JL; Lee MS; Hu AY; Lin SC; Huang YY; Hu MH; Chow YH; Chiang JR; Chang JY; Chong P
PLoS One; 2012; 7(4):e34834. PubMed ID: 22529942
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B virus core particles containing multiple epitopes confer protection against enterovirus 71 and coxsackievirus A16 infection in mice.
Huo C; Yang J; Lei L; Qiao L; Xin J; Pan Z
Vaccine; 2017 Dec; 35(52):7322-7330. PubMed ID: 29129453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
